Literature DB >> 22611169

NICE recommends abiraterone for prostate cancer after manufacturer reduces price.

Zosia Kmietowicz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22611169     DOI： 10.1136/bmj.e3520

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Cross-national comparison of medical costs shared by payers and patients: a study of postmenopausal women with early-stage breast cancer based on assumption case scenarios and reimbursement fees.

Authors:  Shota Hamada; Shiro Hinotsu; Hiroshi Ishiguro; Masakazu Toi; Koji Kawakami
Journal:  Breast Care (Basel)       Date:  2013-08       Impact factor: 2.860

2.  Improving care and reducing costs in oncology.

Authors:  Giovanni Codacci-Pisanelli
Journal:  Ecancermedicalscience       Date:  2013-12-03

3.  Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study.

Authors:  Jin-Ge Zhao; Jian-Dong Liu; Peng-Fei Shen; Xin Tang; Guang-Xi Sun; Xing-Ming Zhang; Jun-Ru Chen; Kun-Peng Shu; Ming Shi; Hao Zeng
Journal:  Asian J Androl       Date:  2018 Nov-Dec       Impact factor: 3.285
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.